CYP19A1 and breast carcinoma: The higher rate of ESR1 mutations in primary tumors (3%) in this study is probably related to the fact that patients enrolled in the BOLERO-2 clinical trial had advanced breast cancer and had disease progression or recurrence after treatment with an aromatase inhibitor (letrozole or anastrozole).